In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Idera Pharmaceuticals, Inc.

https://www.aceragen.com

Latest From Idera Pharmaceuticals, Inc.

Scrip Asks…What Does 2023 Hold For Biopharma? Part 8: Therapeutic Area Advances

Neuroscience and oncology fuel high hopes for therapeutic R&D progress among 90-plus surveyed biopharma industry leaders.

Scrip Asks Research & Development

Deal Watch: Adaptimmune, TCR2 Join Forces As Cell Therapy Company Focused On Solid Tumors

All-stock merger will create new company owned 75% by Adaptimmune’s shareholders. Grifols, Selagine to explore antibody approach to treating dry eye disease, and other recent deals.

Deal Watch Business Strategies

Protagonist/J&J Explore Autoimmune FRONTIER With Positive Psoriasis Results

While full data are not yet available, JNJ-2113 would be the first oral drug against IL-23R, setting up for potential competition against oral TYK2 and IL-17-targeting drugs.

Clinical Trials Inflammation

Worldwide Regulators Warm Up To Medical Marijuana

Both the US and EU are gradually warming up to medical marijuana, but clunky and inadequate regulation threatens to curtail the growth of a burgeoning industry.

Cannabidiol CBD Regulation
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
  • Other Names / Subsidiaries
    • Hybridon Inc.
    • Idera Pharmaceuticals, Inc.
    • Idera Pharmaceuticals
UsernamePublicRestriction

Register